Johnson & Johnson vs. Pacira BioSciences, Inc. Common Stock
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| JNJ | PCRX | |
|---|---|---|
| Market Cap | $622.84 billion | $1.00 billion |
| Revenue (TTM) | $97.93 billion | $746.16 million |
| Net Income (TTM) | $21.04 billion | $14.64 million |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | PCRX | |
|---|---|---|
| P/E Ratio | 29.75 | 103.97 |
| Price / Book | 7.33 | 1.49 |
| Price / Sales | 6.36 | 1.35 |
PCRX leads on 2 of 3 valuation factors.
Profitability
| JNJ | PCRX | |
|---|---|---|
| Net Margin | 21.48% | 1.96% |
| Return on Equity | 24.76% | 2.18% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | PCRX | |
|---|---|---|
| Dividend Yield | 2.09% | — |
| Payout Ratio | 62.18 | — |
JNJ and PCRX split the dividend factors evenly.
Risk & Sentiment
| JNJ | PCRX | |
|---|---|---|
| Short Interest | 0.67% | 9.32% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, PCRX overview, PCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.